The Chaim Sheba Medical Center - Sheba Cancer Research Center (SCRC)
Welcome,         Profile    Billing    Logout  
 12 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Golan, Talia
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
PROTACT, NCT01676259: A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
2
80
US, RoW
siG12D-LODER, Gemcitabine+nab-Paclitaxel, Chemotherapy, Folfirinox
Silenseed Ltd
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
10/22
08/23
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT03838029: Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery

Recruiting
2
210
RoW
Propranolol and etodolac, Deralin and etopan, Placebo
Assaf-Harofeh Medical Center, Sheba Medical Center
Pancreatic Neoplasms
01/26
01/26
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Recruiting
1/2
120
RoW
Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
03/25
03/25
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
PanC-ASAP, NCT04431258 / 2020-002791-13: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Completed
1/2
150
Europe, US, RoW
ABTL0812, Folfirinox, Chemotherapy, Placebo
Ability Pharmaceuticals SL, Ability Pharmaceuticals, SL
Pancreatic Cancer
01/24
01/24
NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Active, not recruiting
1
101
Europe, Japan, US, RoW
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumors Cancer
05/26
05/26
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
CA184-604, NCT05088889: Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Recruiting
1
10
RoW
Nivolumab, ipilimumab, Stereotactic body radiation therapy, SBRT, Low dose irradiation
Sheba Medical Center, Bristol-Myers Squibb
Stage IV Pancreatic Cancer
07/24
07/24
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
NCT01983410: A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Recruiting
N/A
600
US, RoW
The risk assessment questionnaire, Blood specimens, tumor tissue samples will be requested
Memorial Sloan Kettering Cancer Center, Abramson Cancer Center at Penn Medicine, Shaare Zedek Medical Center, Sheba Medical Center, Dana-Farber Cancer Institute, Johns Hopkins University
Pancreatic Ductal Adenocarcinoma
11/25
11/25
NCT03334708: A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting
N/A
700
US, RoW
Blood Draw, Tumor Tissue Collection, Cyst Fluid
Memorial Sloan Kettering Cancer Center, Sheba Medical Center, Weill Medical College of Cornell University, Weizmann Institute of Science
Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
10/25
10/25
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
10000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30

Download Options